GlassScriptPhysician profile
Steven R Garner
NPI 1477546281
$6,707.10
in general payments reported to CMS, 2019-2025
53 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $527 · 2021: $985 · 2022: $1,113 · 2023: $979 · 2024: $1,131 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,213.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $980.15 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $501.43 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $477.05 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $467.36 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $439.23 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $416.02 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $338.11 | 2019-2023 | Trulance, Xifaxan |
| Abbvie INC. | $327.26 | 2021-2025 | |
| Pfizer INC. | $294.38 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $220.53 | 2021-2024 | |
| Amgen INC. | $144.96 | 2019-2025 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $135.07 | 2019-2025 | Wegovy |
| Daiichi Sankyo INC. | $110.16 | 2022-2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $108.84 | 2023-2025 | Rexulti |
| Noven Therapeutics, LLC | $107.34 | 2023-2025 | Xelstrym |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.